Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity - Induced by 1-methyl-4-(2′-methylphenyl)-1,2,3,6- tetrahydropyridine (2′-methyl-MPTP) in mice

Journal of Biochemical and Molecular Toxicology

Volumn 19, Issue 1, 2005, Pages 32-41

  Abdel Wahab, M H ^a  

^a Al Azhar University   (Egypt)

Author keywords

2 CH3 MPTP; Brain Stem; Mice; Oxidative Stress; TBHQ

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 (2 METHYLPHENYL)PYRIDINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLUTATHIONE; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TERT BUTYLHYDROQUINONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN EDEMA; BRAIN STEM; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; HISTOPATHOLOGY; MALE; MOUSE; NERVE CELL LESION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN CONTENT; STRIATONIGRAL DEGENERATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN STEM; CELL NUCLEUS; GLUTATHIONE; HYDROQUINONES; MALE; MALONDIALDEHYDE; MICE; MPTP POISONING; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; SUPEROXIDE DISMUTASE;

ANIMALIA;

EID: 14644436461     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbt.20053     Document Type: Article

References (37)

1. Sonsalla PK, Youngster SK, Kindt MV, Heikkila RE. Characteristics of 1-methyl-4-(2′-methylphenyl) 1,2,3,6,tetrahydropyridine induced neurotoxicity in the mouse. J Pharmacol Exp Ther 1987;242(3):850-857.
2. Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brain stem nuclei to Alzheimer's disease. Ann Neurol 2001;49:53-66.
3. Andrews AM, Murphy DL. Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4- (2′-aminophenyl)-1,2,3,6-tetrahydropyridine (2′-NH2-MPTP): A comparative study with 2′-CH3-MPTP and MPTP. J Neurochem 1993;60:1167-1170.
4. Chiueh CC, Huang SJ, Mutrphy DL. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: Suspension by clorgyline and deprenyl. Synapse 1992;11(4):346-348.
5. Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm 2002;109(9):1159-1180.
6. Fahn S, Cohen G. The oxidative stress hypothesis in Parkinson's disease. Evidence supporting it. Ann Neurol 1992;32:804-812.
7. 12 cells and cerebellar granular cells: Possible implication in the etiology of Parkinson's disease. Neurosci Lett 1999;260:101-104.
8. + neurotoxicity against rat dopaminergic neurons in culture. Neurosci Lett 1995;193:53-56.
9. Kostrzewa RM, Segura-Aguilar J. Neurotoxicological and neuroprotective elements in Parkinson's disease. Neurotox Res 2002;4:83-86.
10. Nishizono S, Hayami T, Ikeda I, Imaizumi K. Protection against the diabetogenic effect of feeding tert-butyl hydroquinone to rats prior to the administration of streptozotocin. Biosci Biotechnol Biochem 2000;64(6):1153- 1158.
11. Parfitl K. Martindale, the complete drug reference, 32nd edition. London; Pharmaceutical Press; 1999. p 1126.
12. Ahmed AE, Nouraleen AM, Abdel-Rhman SZ, Rajarman S. Role of glutathione modulation in acrylonitrile-induced gastric DNA damage in rats. Arch Toxicol 1996;70(10):620-627.
13. Monroe DH, Eaton DL. Comparative effects of butylated hydroxyanisole on hepatic in vivo DNA binding and in vitro biotransformation of aflatoxin B1 in the rat and mouse. Toxicol Appl Pharmacol 1987;90(3):401-409.
14. Barcelo D, Maris FA, Geedlink RB, Frei RW, de Jong GJ, Brinkman UA. Comparison between positive, negative and chloride-enhanced negative chemical ionization of organophosphorus pesticides in on-line liquid chromatography- mass spectrometry. J Chromatogr 1987;8:65-76.
15. Cummings SW, Prough RA. Butylated hydroxyanisole-stimulated NADPH oxidase activity in rat liver microsomal fractions. J Biol Chem 1983;258(20):12315- 12319.
16. Rushmore TH, M Orton MR, Pickett CB. The antioxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 1991;266(18):11632-11639.
17. Bernardini GL, Speciale SG, German DC. Increased midbrain dopaminergic cell activity following 2′ CH3-MPTP- induced dopaminergic cell loss: An in vitro electrophysiological study. Brain Res 1990;527(1):123-129.
18. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl group in tissue with Ellman's reagent. Anal Biochem 1968;25(1):192-205.
19. Eftekhar EP, Aene H, Bernhord HJ. Thioredoxin reductase and glutathione synthesis is regulated by TBHQ in cortical astrocytes but not in cortical neurons. GILA 2000;31:241-248.
20. Kosower NS, Kosower EM. The glutathione status of cells. Int Rev Cytol 1978;54:109-160. Review.
21. Marklaund SL. Pyrogallol autooxidation. In: Greenwald RA, editor Handbook of methods for oxygen radical research. Boca Raton, Fl: CRC Press; 1985. pp 243-247.
22. Minami M, Yoshikawa H. A simplified assay method of superoxide dismutase activity for clinical use. Clin Chim Acta 1979;92(3):337-342.
23. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbiruric acid test. Anal Biocem 1978;86(1):271-278.
24. Hillarp NA, Hokfelt B. Evidence of adrenaline and noradrenaline in separate adrenal medullary cells. Acta Physiol 1953;30(1):55-68.
25. Piezzi RS, Bianchi RA, Miranda JC. Chromaffin reactions and fluorometric determination of catecholamines in the neonatal adrenal medulla of the rat. J Histochem Cytochem 1983;31(12):1351-1355.
26. Kim YS, Joo WS, Jin BK, Cho YH, Baik HH, Park CW. Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system. Neuroreport 1998;9(10):2387-2390.
27. Furuya T, Hayakawa H, Yamada M, Yoshimi K, Hisahara S, Miura M, Mizuno Y, Mochizuki H. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydopyridine mouse model Parkinson's tetrahydropyridine. J Neurosci 2004;24(8):1865-1872.
28. 14C]-chloroacetonitrile (CAN) quantitative whole-body autoradiographic study in pregnant mice. Toxicol Ind Health 1998;14(4):533-546.
29. Kempf E, Mandel P. Reverse-phase high-performance liquid chromatographic separation and electrochemical detection of norepinepherine, dopamine, serotonin and related major metabolites. Anal Biochem 1981;112(2):223-231.
30. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993;16(11):439-444.
31. Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 2004;186(2):109-111.
32. Mandavilli BS, Ali SF, Van Houten B. DNA damage in brain treatment. Brain Res 2000;885(1):45-52.
33. Joo WS, Jin BK, Park CW, Maeng SH, Kim YS. Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. Neuroreport 1998;9:4123-4126.
34. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DG, Luecke S, Phebus LA, Bymaster FB, Paul S. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98(25):14669-14674.
35. Reinhard JF Jr, Daniels AJ. Subcellular compartmentation of 2′-methyl MPPT can explain differences in toxicity to adrenal chromaffin cells. Ann NY Acad Sci 1992;648:323-325.
36. Abdel-Wahab MH. Testicular toxicity of dibromoacetonitrile and possible protection by tertiary butylhydroquinone. Pharmacol Res 2003;47:509-515.
37. Badary OA, Taha RA, Gamal El-Din AM, Abdel-Wahab MH. Thymoquinone is a potent superoxide anion scavenger. Drug Chem Toxicol 2003;26(2):87-98.